<i>In Vivo–In Vitro</i> Correlations: Predicting Pulmonary Drug Deposition from Pharmaceutical Aerosols
Peter R. Byron(Virginia Commonwealth University), Warren H. Finlay(University of Alberta), Charles G. Thiel, Michael Hindle(Virginia Commonwealth University), Bo Olsson(AstraZeneca (Sweden)), Michael J. Oldham(Virginia Commonwealth University), P. Worth Longest(Virginia Commonwealth University), Carlos F. Lange(University of Alberta), Herbert Wachtel(Boehringer Ingelheim (Germany)), Donald W. McRobbie
Cited by 115
Related Papers
Comparing MDI and DPI Aerosol Deposition Using In Vitro Experiments and a New Stochastic Individual Path (SIP) Model of the Conducting Airways
|Pharmaceutical Research|2012|185
Determination of the relative bioavailability of salbutamol to the lung following inhalation [see comments]
|British Journal of Clinical Pharmacology|1992|166
Use of computational fluid dynamics deposition modeling in respiratory drug delivery
|Expert Opinion on Drug Delivery|2018|142
Comparison of ambient and spray aerosol deposition in a standard induction port and more realistic mouth–throat geometry
|Journal of Aerosol Science|2008|127
Validating CFD Predictions of Pharmaceutical Aerosol Deposition with In Vivo Data
|Pharmaceutical Research|2015|111